Olema Oncology
Graham Walmsley, MD PhD, is a prominent figure in the biotechnology and healthcare sectors, co-founding and serving as Managing Partner at Logos Global Management, LP since August 2019. Walmsley holds board positions at Olema Oncology and Akero Therapeutics, and has previously served on the boards of several companies, including 35Pharma and ALX Oncology. With experience as a Principal at Versant Ventures and board observer roles at various therapeutics firms, Walmsley brings extensive expertise in the industry. Educational credentials include an MD and PhD in Stem Cell Biology & Regenerative Medicine from Stanford University School of Medicine, coupled with a summa cum laude Bachelor of Arts in Molecular and Cell Biology from the University of California, Berkeley.
This person is not in any teams
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.